Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LCT antisense RNA 1 (LCT-AS1) is a human long non-coding RNA gene located antisense to the *LCT* locus. As with many antisense lncRNAs, LCT-AS1 regulates gene expression, including potential post-transcriptional regulation and gene silencing[1][3][5]. Studies indicate a role in regulating BMI1 via microRNA interaction, such as sponging miR-128-1-3p in Hirschsprung’s disease[3]. LCT-AS1 may also influence the *LCT* gene's function, affecting traits like lactose tolerance, although direct mechanistic links remain under investigation[5]. There is no current evidence that it serves as a direct target for pharmacological intervention, but its general class—antisense lncRNAs—is increasingly recognized for regulatory, epigenetic, and disease-associated roles[1]. No evidence suggests LCT-AS1 is a druggable target or is involved in receptor, enzyme, or transporter functions. Its modulation is mainly regulatory, through RNA-based mechanisms, and research is ongoing regarding broader disease or drug implications[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LCT antisense RNA 1 (LCT-AS1).